AVALANCHE BIOTECHNOLOGIES IN - COM (AAVL)

CUSIP: 05337G107

Q3 2015 13F Holders as of 30 Sep 2015

Type / Class
Equity / COM
Total 13F shares
17,435,479
Share change
+1,507,714
Total reported value
$143,669,248
Put/Call ratio
232%
Price per share
$8.24
Number of holders
90
Value change
+$4,723,424
Number of buys
53
Number of sells
46

Quarterly Holders Quick Answers

What is CUSIP 05337G107?
CUSIP 05337G107 identifies AAVL - AVALANCHE BIOTECHNOLOGIES IN - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of AVALANCHE BIOTECHNOLOGIES IN - COM (AAVL) as of Q3 2015

As of 30 Sep 2015, AVALANCHE BIOTECHNOLOGIES IN - COM (AAVL) was held by 90 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 17,435,479 shares. The largest 10 holders included FMR LLC, CADIAN CAPITAL MANAGEMENT, LP, VHCP Management, LLC, BlackRock Fund Advisors, Redmile Group, LLC, NUMERIC INVESTORS LLC, AXA, SABBY MANAGEMENT, LLC, VANGUARD GROUP INC, and BALYASNY ASSET MANAGEMENT LLC. This page lists 90 institutional shareholders reporting positions in this security for the Q3 2015 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.